Abbonarsi

Clinical and spirometric variables are better predictors of COPD exacerbations than routine blood biomarkers - 09/09/20

Doi : 10.1016/j.rmed.2020.106091 
Alexa Nuñez a, 1, Viviana Marras b, 1, Matevz Harlander c, d, Evgeni Mekov e, Matjaz Turel c, Rossen Petkov e, David Lestan c, Nikolay Yanev e, Silvia Negri b, Miriam Barrecheguren a, Pietro Pirina b, Marc Miravitlles a, f, , Cristina Esquinas a
a Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain 
b Respiratory Unit, AOU Sassari, Sassari, Italy 
c Department of Pulmonary diseases, University Medical Centre Ljubljana, Slovenia 
d Faculty of Medicine, University of Ljubljana, Slovenia 
e Department of Pulmonary Diseases, Medical Faculty, Medical University of Sofia, Bulgaria 
f CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain 

Corresponding author. Pneumology Department, Hospital Universitari Vall d'Hebron P, Vall d’Hebron 119, Barcelona, Spain.Pneumology DepartmentHospital Universitari Vall d'Hebron PVall d’Hebron 119BarcelonaSpain

Abstract

Background

Understanding the risk factors for exacerbations of COPD may help provide a more personalised approach to exacerbation prevention.

Method

Observational, prospective, international, multicentre study aimed at identifying risk factors for exacerbations of COPD. Clinical variables, lung function and CAT scores were collected at baseline. In addition, routine blood biomarkers were also obtained, and patients were followed for 12 months.

Results

A total of 326 patients were included. Of these, 155 (47.5%) presented at least one exacerbation. The median time to the first exacerbation was 147 days. Exacerbators had more respiratory symptoms, more impairment in FEV1(%), FVC(%) and a worse CAT score. Regarding biomarkers, only C-reactive protein was significantly higher in exacerbators (2.8 (standard deviation (SD):3.8) mg/dL vs. 1.9 (SD:2.6) mg/dL; p = 0.037). In multivariate analysis, only CAT scores, FEV1(%) and previous exacerbations were significantly associated with having an exacerbation during follow-up. In the equation of risk, patients with a CAT score ≥15, FEV1(%) <55% and at least one exacerbation the previous year had a probability of 76% of having an exacerbation during the next year, compared with 17% in patients who had none of the previous variables. No biomarkers showed a significant association in multivariate analysis.

Conclusions

Less than half of the patients presented an exacerbation during the one-year follow-up. CAT scores, FEV1(%) and previous exacerbations were the only variables associated with increased risk of exacerbations. Routine biomarkers did not provide additional information to evaluate the risk of exacerbations.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Approximately half of the COPD patients had an exacerbation during one-year follow-up.
CAT, FEV1(%) and previous exacerbations were predictive for future exacerbations.
No routine blood biomarker provided additional predictive value.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Exacerbations, COPD, CAT, Prevention, Biomarkers


Mappa


© 2020  Elsevier Ltd. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 171

Articolo 106091- settembre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • The association of anxiety and depression with mortality in a COPD cohort. The HUNT study, Norway
  • Sigrid Anna Aalberg Vikjord, Ben Michael Brumpton, Xiao-Mei Mai, Lowie Vanfleteren, Arnulf Langhammer
| Articolo seguente Articolo seguente
  • Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life
  • Elisabeth Arndal, Anne Lyngholm Sørensen, Therese Sophie Lapperre, Nihaya Said, Charlotte Trampedach, Kasper Aanæs, Mikkel Christian Alanin, Karl Bang Christensen, Vibeke Backer, Christian von Buchwald

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.